Cannabidiol for Alcoholism

(CAP Trial)

HC
RB
Overseen ByRachel Baechtold, M.S.
Prior Safety DataThis treatment has passed at least one previous human trial

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial aims to determine if Full-Spectrum CBD (which includes a small amount of THC) or Broad-Spectrum CBD (no THC) can help reduce alcohol consumption and improve mood in individuals with Alcohol Use Disorder (AUD). Participants will be randomly assigned to take either Full-Spectrum CBD, Broad-Spectrum CBD, or a placebo daily for 8 weeks. Researchers will also examine how these treatments affect the gut. This trial suits adults diagnosed with moderate or severe AUD, who consume at least 20 drinks a week, and have at least one heavy drinking day per week. As a Phase 2 trial, this research measures the treatment's effectiveness in an initial, smaller group, allowing participants to contribute to important findings.

Will I have to stop taking my current medications?

You may need to stop taking certain medications to participate in this trial. Specifically, you cannot take medications that interact with Epidiolex or Marinol, certain antiepileptic or psychotropic medications, or medications that affect alcohol intake. If you're on antidepressants, you must be on a stable dose for the past 90 days.

Is there any evidence suggesting that this trial's treatments are likely to be safe?

Research shows that both Full-Spectrum CBD (fs-CBD) and Broad-Spectrum CBD (bs-CBD) are generally safe. Earlier studies found that participants tolerated both types well, with side effects usually mild and less serious than those from other addiction treatments. No major safety differences appeared between the two types of CBD.

However, using CBD with alcohol or certain drugs might not be safe. Report any side effects to your healthcare provider. Overall, research suggests that CBD treatments are promising and safe for use.12345

Why are researchers excited about this trial's treatments?

Researchers are excited about these treatments because they offer a new approach to tackling alcoholism by using cannabidiol (CBD). Unlike traditional treatments that often focus on behavioral therapies or medications like disulfiram and naltrexone, CBD works by potentially interacting with the brain's endocannabinoid system, which might help reduce cravings and anxiety associated with alcohol use. Full-spectrum CBD includes a tiny amount of THC, which might enhance its therapeutic effects, while broad-spectrum CBD excludes THC entirely, offering a non-psychoactive alternative. This dual approach provides a promising new avenue for individuals looking for alternatives to conventional alcoholism treatments.

What evidence suggests that this trial's treatments could be effective for Alcohol Use Disorder?

This trial will compare the effects of full-spectrum CBD (fs-CBD) and broad-spectrum CBD (bs-CBD) on alcohol consumption and cravings. Research has shown that both fs-CBD and bs-CBD may help reduce the urge to drink alcohol and lower overall alcohol consumption. One study found that fs-CBD was more effective than bs-CBD in reducing alcohol cravings and symptoms of Alcohol Use Disorder (AUD). Other research indicates that CBD can decrease how often people drink and their desire to consume alcohol. CBD might work by altering how the brain reacts to stress and triggers related to alcohol. Both types of CBD may help by calming the brain's response to alcohol and making it less appealing.25678

Who Is on the Research Team?

HC

Hollis C Karoly, PhD

Principal Investigator

University of Colorado School of Medicine- Anschutz Medical Campus

Are You a Good Fit for This Trial?

This trial is for adults with Alcohol Use Disorder (AUD) who may also experience alcohol-related intimate partner violence. Participants will be involved in the study for 12 weeks, taking a daily dose of either Full-Spectrum CBD, Broad-Spectrum CBD, or placebo and reporting their alcohol use.

Inclusion Criteria

Provides informed consent to participate
Willing to provide fecal samples
Willing to have their blood drawn
See 5 more

Exclusion Criteria

Must not be positive for any illicit drugs (besides cannabis) on urine drug screen or self-report any illicit/recreational drug use in the past 30 days
Must not report a history of alcohol-related liver disease or alcohol-related medical illness
Must not be seeking treatment/in treatment for AUD or another substance use disorder
See 11 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants take the assigned study drug (fs-CBD, bs-CBD, or placebo) daily for 8 weeks, report alcohol use via daily surveys, and attend 5 in-person study visits with weekly virtual check-ins.

8 weeks
5 visits (in-person), weekly virtual check-ins

Follow-up

Participants are monitored for changes in alcohol consumption and AUD phenotypes, with assessments at baseline, week 4, week 8, and week 12.

4 weeks
2 visits (in-person)

What Are the Treatments Tested in This Trial?

Interventions

  • Broad-Spectrum Cannabidiol (CBD)
  • Full-Spectrum Cannabidiol (CBD)

Trial Overview

The study tests if Full-Spectrum CBD (with a bit of THC) or Broad-Spectrum CBD (no THC) can reduce alcohol consumption and improve emotional states compared to a placebo. It also examines the effects on gut health over an 8-week period with regular check-ins and five in-person visits.

How Is the Trial Designed?

3

Treatment groups

Experimental Treatment

Placebo Group

Group I: Full-Spectrum CBDExperimental Treatment1 Intervention
Group II: Broad- Spectrum CBDExperimental Treatment1 Intervention
Group III: PlaceboPlacebo Group1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

University of Colorado, Denver

Lead Sponsor

Trials
1,842
Recruited
3,028,000+

National Institute on Alcohol Abuse and Alcoholism (NIAAA)

Collaborator

Trials
865
Recruited
1,091,000+

Citations

CBD for the Treatment of Alcohol Use Disorder

The current study will directly test the hypothesis that a moderate dose of CBD leads to a reduction in alcohol consumption, alcohol craving, peripheral markers ...

A preliminary randomized trial of the safety, tolerability, and ...

For example, CBD reduces the reinforcing properties of alcohol and decreases alcohol consumption frequency and drinking motivation (18, 19). CBD ...

Study protocol for a double-blind, randomised, cross over ...

CBD could reduce alcohol craving and seeking due to moderating responses to alcohol and stress cues, normalising dysregulated neurobiological systems and/or ...

Cannabidiol mitigates alcohol dependence and withdrawal ...

This study investigated the effects of chronic CBD administration on alcohol dependence, withdrawal symptoms, and neurodegeneration using two complementary ...

NCT05613608 | Alcohol Use Disorder and Cannabidiol

The current study will directly test the hypothesis that a moderate dose of CBD leads to a reduction in alcohol consumption, alcohol craving, peripheral markers ...

6.

pubmed.ncbi.nlm.nih.gov

pubmed.ncbi.nlm.nih.gov/40357520/

A preliminary randomized trial of the safety, tolerability, and ...

In this pilot study, safety profiles fsCBD and bsCBD were similar, and fsCBD was associated with a greater reduction in craving and AUD ...

A preliminary randomized trial of the safety, tolerability, and ...

In this pilot study, safety profiles fsCBD and bsCBD were similar, and fsCBD was associated with a greater reduction in craving and AUD symptoms relative to ...

Cannabidiol (CBD) – Potential Harms, Side Effects, and ...

Do not use CBD concurrently with medications, alcohol, or illicit drugs. ○ If you experience adverse events as a result of using CBD products, report them to ...